Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,147 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Autologous Transplantation Clear all
Completed Phase 1Phase 2 Interventional Results available

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

NCT02059239
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Carmustine, Etoposide, Melphalan, Cytarabine, Alemtuzumab, Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

NCT01458366
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Ofatumumab, Carboplatin, Etoposide, CT Scan, PET Scan, Stem Cell Transplant (STC)
Drug · Procedure · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 25, 2026, 2:41 PM EDT
Withdrawn Phase 1 Interventional

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

NCT00504101
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Arsenic trioxide, Bortezomib, Melphalan, Autologous hematopoietic stem cell transplantation
Drug · Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 25, 2026, 2:41 PM EDT
Terminated Phase 1 Interventional Results available

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

NCT02483000
View directory record Official record
Conditions
Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Clearing Agent, Cytarabine, Etoposide, Indium In 111-DOTA-Biotin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Yttrium Y 90-DOTA-Biotin
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Bone-void Filler on Anterior Knee Pain Following ACL Reconstruction

NCT04533880
View directory record Official record
Conditions
ACL
Interventions
DBM, Calcium phosphate cement, Autologous bone graft
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Multi-center Study to Assess Posterolateral Fusion Using FIBERGRAFT

NCT03884283
View directory record Official record
Conditions
Degenerative Disc Disease, Spondylolisthesis, Spinal Stenosis Lumbar
Interventions
FIBERGRAFT BG Matrix
Device
Lead sponsor
Prosidyan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
9
States / cities
Long Beach, California • Wellington, Florida • Paducah, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 4 Interventional Results available

Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following ACL Reconstruction With Bone Patellar Tendon Bone Autograft:

NCT05286307
View directory record Official record
Conditions
Anterior Cruciate Ligament Rupture
Interventions
IPACK block
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

NCT01437709
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 25, 2026, 2:41 PM EDT
Terminated Not applicable Interventional Results available

Use of Platelet Rich Plasma After Arthroscopic Debridement for Triangular Fibrocartilage Complex Tears

NCT03805698
View directory record Official record
Conditions
Arthroscopic Surgery, Triangular Fibrocartilage Complex Injury
Interventions
Platelet-rich Plasma (PRP), Standard Arthroscopic Debridement
Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 25, 2026, 2:41 PM EDT
Not listed Phase 1Phase 2 Interventional

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00002628
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
3
States / cities
Indianapolis, Indiana • St Louis, Missouri • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous and Allogeneic Transplant for Relapsed Lymphoma

NCT00802113
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkins Disease
Interventions
Fludarabine, Busulfan, Anti-Thymocyte Globulin
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 25, 2026, 2:41 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Cardiac Safe Transplants for Systemic Sclerosis

NCT03593902
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 25, 2026, 2:41 PM EDT
Recruiting No phase listed Observational

Taking Measurements of a Gum Graft Site as it Heals

NCT07386457
View directory record Official record
Conditions
Gingival Recession
Interventions
Gingival graft surgery to treat gingival recession
Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00002805
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
35
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 25, 2026, 2:41 PM EDT
Recruiting Phase 2 Interventional

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

NCT06974786
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 2:41 PM EDT
Recruiting Phase 2 Interventional

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

NCT05776979
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 2:41 PM EDT
Recruiting No phase listed Observational

Analysis of Graft Function Following Autologous Islet Transplantation

NCT03097185
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission

NCT00002768
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, busulfan, cytarabine, etoposide, methotrexate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years to 69 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

NCT00238368
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 4 Interventional

A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting

NCT04516148
View directory record Official record
Conditions
Burn, Surgery, Infection Wound
Interventions
Cefazolin, Clindamycin
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Not applicable Interventional

Human Breastmilk in Children Receiving a Bone Marrow Transplant

NCT02025478
View directory record Official record
Conditions
Bone Marrow Transplant- Autologous or Allogeneic
Interventions
Breastmilk
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 5 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 25, 2026, 2:41 PM EDT
Active, not recruiting No phase listed Observational

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

NCT02633943
View directory record Official record
Conditions
Transfusion-dependent Beta-Thalassemia
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
0 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2035
U.S. locations
6
States / cities
Oakland, California • Chicago, Illinois • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 25, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

NCT00288626
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
4
States / cities
Columbus, Ohio • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 25, 2026, 2:41 PM EDT